ما هو علاج مرض السكري الكاذب المركزي؟

References

• Treatment of CDI depends on the pharmaceutical replacement of AVP with desmopressin, a synthetic analog of the hormone, modified to prolong half-life and diminish vasoconstrictor effects (at the V1 receptor).
• Oral dDAVP is preferred to nasal spray by most patients due to the ease of administration and the continued efficacy when nasal congestion occurs due to coryzal infection.
• Oral preparations include both standard tablets and sublingual preparations "desmotabs melt," both of which are in common use.
• The intranasal formulation of dDAVP was the earliest treatment for chronic CDI.
• Abolition of symptoms of polyuria and polydipsia.
• Avoidance of hyponatremia secondary to treatment.
• Symptomatic relief occurs almost immediately after starting dDAVP, with effective long-term control of polyuria.